Daewoong Pharmaceutical's Fexuclu Gains Additional Indication for Helicobacter pylori Eradication
Approval for P-CAB-Based Combination Therapy
Improved Eradication Rates in Resistant Patients
Daewoong Pharmaceutical announced on May 4 that its gastroesophageal reflux disease treatment, Fexuclu Tab. 40mg (ingredient: fexuprazan hydrochloride), has received additional approval from the Ministry of Food and Drug Safety for use in combination antibiotic therapy for the eradication of Helicobacter pylori.
With this approval, the scope of Fexuclu has been expanded beyond its existing indications—treatment of erosive gastroesophageal reflux disease, improvement of gastritis, and prevention of NSAID-induced peptic ulcers—to now include Helicobacter pylori eradication therapy.
Helicobacter pylori is identified as a major cause of chronic gastritis, gastric ulcers, and gastric cancer, with a relatively high prevalence in South Korea. However, increasing antibiotic resistance has been cited as a reason for declining success rates in existing eradication therapies. According to Daewoong Pharmaceutical, Fexuclu, which belongs to the P-CAB class of gastric acid suppressants, is characterized by its rapid and potent acid suppression as well as dosing convenience. When used in combination with antibiotics, it can maintain stable gastric acidity, which is a significant advantage in enhancing eradication efficacy.
This additional indication was based on the results of a Phase 3 clinical trial conducted in South Korea from February 2024 to April 2025. The study confirmed the efficacy and safety of Fexuclu-based combination therapy. Notably, in the group of patients with clarithromycin resistance, the eradication rate for Fexuclu-based therapy was 54.76%, approximately 26 percentage points higher than the 28.57% observed with the conventional lansoprazole-based therapy.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seongsu Park, CEO of Daewoong Pharmaceutical, stated, "This additional indication is significant as it expands Fexuclu's therapeutic range beyond gastroesophageal reflux disease and gastritis to now include the eradication of Helicobacter pylori, an infection-based gastrointestinal disease."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.